Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Bleomycin; Procarbazine; Vincristine; Vinblastine; Etoposide; Dacarbazine; Doxorubicin; Cyclophosphamide; Prednisone; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Positron-Emission Tomography/methods; Young Adult; Hodgkin Disease/diagnostic imaging; Hodgkin Disease/drug therapy; Neoplasms, Second Primary/pathology; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Neoplasms, Second Primary; Positron-Emission Tomography; Oncology; Cancer Research
Disciplines :
Hematology
Author, co-author :
Casasnovas, René-Olivier ; Department of Hematology, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France
Bouabdallah, Reda; Department of Hematology, Institut P. Calmette, Marseille, France ; Department of Hematology, Hopital privé de Provence, Aix en Provence, France
Brice, Pauline; Department of Hematology, APHP, Hopital Saint Louis, Paris, France
Lazarovici, Julien; Department of Hematology, Institut G. Roussy, Villejuif, France
Ghesquieres, Hervé; Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, et Université Claude Bernard Lyon-1, Pierre Bénite, France
Stamatoullas, Aspasia ; Department of Hematology, Centre H. Becquerel, Rouen, France
Dupuis, Jehan; Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France
Gac, Anne-Claire; Department of Hematology, Institut d'hématologie de basse normandie, Caen, France
Gastinne, Thomas; Department of Hematology, University Hospital of Nantes, Nantes, France
Joly, Bertrand ; Department of Hematology, Hospital Sud Francilien, Corbeille-Essonnes, France
Bouabdallah, Krimo; Department of Hematology, University Hospital of Bordeaux, Bordeaux, France
Nicolas-Virelizier, Emmanuelle; Department of Hematology, Centre L. Bérard, Lyon, France
Feugier, Pierre; Department of Hematology, University Hospital of Nancy, Vandoeuvre les Nancy, France
Morschhauser, Franck ; Department of Hematology, CHU Lille, Unité GRITA, Université de Lille 2, Lille, France
Sibon, David ; Department of Hematology, Hopital Necker, Paris, France
Bonnet, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Berriolo-Riedinger, Alina; Department of Nuclear Medicine, Centre G.F. Leclerc, Dijon, France
Edeline, Véronique; Department of Nuclear Medicine, Hopital R. Huguenin, Institut Curie, St-Cloud, France
Parrens, Marie; Department of Pathology, University Hospital of Bordeaux and Inserm UMR 1053, Bordeaux, France
Damotte, Diane; Department of Pathology, Université de Paris et GH Paris Centre APHP, Paris, France
Coso, Diane; Department of Hematology, Institut P. Calmette, Marseille, France
André, Marc; Department of Hematology, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium ; Pole Mont, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
Meignan, Michel ; Department of Nuclear Medicine, University Hospital H. Mondor, Creteil, France
Rossi, Cédric; Department of Hematology, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Press OW, Li H, Schöder H, et al: US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucosepositron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-2027, 2016
Johnson P, FedericoM, Kirkwood A, et al: Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 374:2419-2429, 2016
Gallamini A, Tarella C, Viviani S, et al: Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 36:454-462, 2018
Borchmann P, Goergen H, Kobe C, et al: PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390:2790-2802, 2018
Casasnovas R-O, Bouabdallah R, Brice P, et al: PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 20:202-215, 2019
Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
Com-Nougue C, Rodary C, Patte C: How to establish equivalence when data are censored: A randomized trial of treatments for B non-Hodgkin lymphoma. Stat Med 12:1353-1364, 1993
Vijenthira A, Chan K, Cheung MC, et al: Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: A modelling study. Lancet Haematol 7:e146-e156, 2020
Kreissl S, Goergen H, Buehnen I, et al: PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): Follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 8:e398-e409, 2021
Kobe C, Goergen H, Baues C, et al: Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood 132:2273-2279, 2018
Demeestere I, Racape J, Dechene J, et al: Gonadal function recovery in patients with advanced Hodgkin lymphoma treated with a PET-adapted regimen: Prospective analysis of a randomized phase III trial (AHL2011). J Clin Oncol 39:3251-3260, 2021
Stephens DM, Li H, Schöder H, et al: Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 134:1238-1246, 2019
von Tresckow B, Kreissl S, Goergen H, et al: Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): Analysis of long-term survival in two randomised trials. Lancet Haematol 5:e462-e473, 2018
Straus DJ, Długosz-Danecka M, Alekseev S, et al: Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-Year update of the ECHELON-1 study. Blood 135:735-742, 2020
Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
Rossi C, Kanoun S, Berriolo-Riedinger A, et al: Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med 55:569-573, 2014
Borchmann P, Plütschow A, Kobe C, et al: PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223-234, 2021
Casasnovas R-O, Ysebaert L, Thieblemont C, et al: FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase 2 study. Blood 130:1315-1326, 2017
Le Gouill S, Ghesquieres H, Obéric L, et al: Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood 137:2307-2320, 2021
Hapgood G, Zheng Y, Sehn LH, et al: Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol 34:2493-2500, 2016
Morschhauser F, Brice P, FerméC, et al: Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: Results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26:5980-5987, 2008
Moskowitz CH, Nademanee A, Masszi T, et al: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl 385: 1853-1862, 2015
Moskowitz CH, Matasar MJ, Zelenetz AD, et al: Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 119:1665-1670, 2012
Josting A, Müller H, Borchmann P, et al: Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 28:5074-5080, 2010
